- Home
- BCLI vs MTEM Comparison
BCLI vs MTEM Comparison
Compare BCLI & MTEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- MTEM
- Stock Information
- Founded
- BCLI 2000
- MTEM 2001
- Country
- BCLI United States
- MTEM United States
- Employees
- BCLI N/A
- MTEM N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- MTEM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BCLI Health Care
- MTEM Health Care
- Exchange
- BCLI Nasdaq
- MTEM Nasdaq
- Market Cap
- BCLI 9.1M
- MTEM 9.7M
- IPO Year
- BCLI N/A
- MTEM N/A
- Fundamental
- Price
- BCLI $2.25
- MTEM $0.35
- Analyst Decision
- BCLI Strong Buy
- MTEM
- Analyst Count
- BCLI 1
- MTEM 0
- Target Price
- BCLI $30.00
- MTEM N/A
- AVG Volume (30 Days)
- BCLI 112.8K
- MTEM 15.2M
- Earning Date
- BCLI 11-14-2024
- MTEM 12-27-2024
- Dividend Yield
- BCLI N/A
- MTEM N/A
- EPS Growth
- BCLI N/A
- MTEM N/A
- EPS
- BCLI N/A
- MTEM N/A
- Revenue
- BCLI N/A
- MTEM $25,470,000.00
- Revenue This Year
- BCLI N/A
- MTEM N/A
- Revenue Next Year
- BCLI N/A
- MTEM N/A
- P/E Ratio
- BCLI N/A
- MTEM N/A
- Revenue Growth
- BCLI N/A
- MTEM N/A
- 52 Week Low
- BCLI $1.05
- MTEM $0.30
- 52 Week High
- BCLI $11.85
- MTEM $4.12
- Technical
- Relative Strength Index (RSI)
- BCLI 70.03
- MTEM 41.77
- Support Level
- BCLI $1.45
- MTEM $0.34
- Resistance Level
- BCLI $1.72
- MTEM $0.78
- Average True Range (ATR)
- BCLI 0.18
- MTEM 0.07
- MACD
- BCLI 0.08
- MTEM 0.01
- Stochastic Oscillator
- BCLI 84.69
- MTEM 5.00
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About MTEM Molecular Templates Inc.
Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer. Its pipeline products are MT-6402, MT-8421 and MT-0169.